Anticancer antibodies

American Journal of Clinical Pathology

Volumn 119, Issue 4, 2003, Pages 472-485

  Ross, Jeffrey S ^a,b   Gray, Karen ^a   Gray, Gary S ^a   Worland, Peter J ^a   Rolfe, Mark ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Antibodies, review; Avastin; Campath; Cancer; Conjugation; Herceptin; Humanization; Mylotarg; Prostate specific membrane antigen; PSMA; Rituxan; Zevalin

Indexed keywords

'CAT'; ACA 125; ADECATUMUMAB; ALEMTUZUMAB; AME; ANTINEOPLASTIC AGENT; AR 54; BB 10901; BEVACIZUMAB; BREVAREX; BZL; CANCER ANTIBODY; CAPECITABINE; CAPROMAB PENDETIDE IN 111; CDP 860; CEAVAC; CETUXIMAB; DACLIZUMAB; EDRECOLOMAB; EMD 72 000; EPRATUZUMAB; G 250; GEMTUZUMAB OZOGAMICIN; GLIOMAB H; H 11; HUJ 591; IBRITUMOMAB TIUXETAN; IGN 010; IGN 101; IMC 1C11; IMUTERAN; ING 1; IOR T1; KSB 303; KW 2871; MDX 210; MDX 220; MONOCLONAL ANTIBODY; MONOPHARM C; MRA; MT 103; ONYVAX 105; OREGOVOMAB; PANITUMUMAB; PROSTATE CANCER ANTIBODY; R 3; RITUXIMAB; SB 408075; SGN 30; THEREX; TOSITUMOMAB I 131; TRASTUZUMAB; TRIAB; TRIGEM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB; ZAMYL;

ACUTE LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; BYSTANDER EFFECT; CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CROSS REACTION; DRUG ANTIGENICITY; DRUG APPROVAL; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; DYSPNEA; FEVER; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOTENSION; HYPOTHYROIDISM; INFECTION; KIDNEY DYSFUNCTION; LIVER DISEASE; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG TOXICITY; MUCOSA INFLAMMATION; MYELODYSPLASIA; NAUSEA; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RIGOR; SIDE EFFECT; SOLID TUMOR; TUMOR CELL DESTRUCTION; VALIDATION PROCESS; VOMITING; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; MALE; MULTIMODALITY CANCER THERAPY; NEOPLASM; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASMS; PROTEIN ENGINEERING;

EID: 85047688463     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/Y6LPC0LR726L9DX9     Document Type: Review

References (91)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
2. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1:118-129.
3. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693-713.
4. Reichert JM. Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr Opin Mol Ther. 2002;4:110-118.
5. Reichert JM. Monoclonal antibodies in the clinic. Nat Biotechnol. 2001;19:819-822.
6. Hemminki A. From molecular changes to customised therapy. Eur J Cancer. 2002;38:333-338.
7. Milenic DE. Monoclonal antibody-based therapy strategies: providing options for the cancer patient. Curr Pharm Des. 2002;8:1749-1764.
8. Reilly RM, Sandhu J, Alvarez-Diez TM, et al. Problems of delivery of monoclonal antibodies: pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet. 1995;28:126-142.
9. Winter G, Harris WJ. Humanized antibodies. Immunol Today. 1993;14:243-246.
10. Merluzzi S, Figini M, Colombatti A, et al. Humanized antibodies as potential drugs for therapeutic use. Adv Clin Path. 2000;4:77-85.
11. Kuus-Reichel K, Grauer LS, Karavodin LM, et al. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol. 1994;1:365-372.
12. Pimm MV. Possible consequences of human antibody responses on the biodistribution of fragments of human, humanized or chimeric monoclonal antibodies: a note of caution. Life Sci. 1994;55:PL45-PL49.
13. Jones PT, Dear PH, Foote J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 1986;321:522-525.
14. Isaacs JD. From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies. Rheumatology. 2001;40:724-738.
15. Watkins NA, Ouwehand WH. Introduction to antibody engineering and phage display. Vox Sang. 2000;78:72-79.
16. Reff ME, Hariharan K, Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control. 2002;9:152-166.
17. Chester KA, Hawkins RE. Clinical issues in antibody design. Trends Biotechnol. 1995;13:294-300.
18. Reff ME, Heard C. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol. 2001;40:25-35.
19. Nielsen UB, Marks JD. Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries. Pharm Sci Technol Today. 2000;3:282-291.
20. Burke JM, Jurcic JG, Scheinberg DA. Radio immunotherapy for acute leukemia. Cancer Control. 2002;9:106-113.
21. Linenberger ML, Maloney DG, Bernstein ID. Antibody-directed therapies for hematological malignancies. Trends Mol Med. 2002;8:69-76.
22. Stevenson GT, Anderson VA, Leong WS. Engineered antibody for treating lymphoma. Recent Results Cancer Res. 2002;159:104-112.
23. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase 11 multicenter trial. Blood. 2002;99:4336-4342.
24. Dillman RO. Monoclonal antibody therapy for lymphoma: an update. Cancer Pract. 2001;9:71-80.
25. Grillo-Lopez AJ, Hedrick E, Rashford M, et al. Rituximab: ongoing and future clinical development. Semin Oncol. 2002;29(1 suppl 2):105-112.
26. Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol. 2002;29(1 suppl 2):30-35.
27. Grillo-Lopez AJ. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Expert Rev Anticancer Ther. 2002;2:323-329.
28. Krasner C, Joyce RM. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma. Curr Pharm Biotechnol. 2001;2:341-349.
29. Gordon LI, Witzig TE, Wiseman GA, et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol. 2002;29(1 suppl 2):87-92.
30. Wagner HN Jr, Wiseman GA, Marcus CS, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267-272.
31. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol. 2002;20:3545-3557.
32. Stadtmauer EA. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia. Clin Lymphoma. 2002;2 suppl 1:S24-S28.
33. Nabhan C, Tallman MS. Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia. Clin Lymphoma. 2002;2 suppl 1:S19-S23.
34. Sievers EL, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol. 2001;13:522-527.
35. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-1496.
36. Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002;16:1627-1636.
37. Dumont FJ. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond. Expert Rev Anticancer Ther. 2002;2:23-35.
38. Pangalis GA, Dimopoulou MN, Angelopoulou MK, et al. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol. 2001;18:99-107.
39. Carswell CI, Plosker GL, Wagstaff AJ. Daclizumab: a review of its use in the management of organ transplantation. BioDrugs. 2001;15:745-773.
40. Kreitman RJ, Chaudhary VK, Kozak RW, et al. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia. Blood. 1992;80:2344-2352.
41. Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol. 2002;29(1 suppl 2):81-86.
42. Cheson BD. Hematologic malignancies: new developments and future treatments. Semin Oncol. 2002;29(4 suppl 13):33-45.
43. Cheson BD. Bexxar (Corixa/GlaxoSmithKline). Curr Opin Investig Drugs. 2002;3:165-170.
44. Rutar FJ, Augustine SC, Kaminski MS, et al. Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine 1131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma. 2001;2:164-172.
45. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
46. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112(1 suppl 1):S53-S67.
47. Huston JS, George AJ. Engineered antibodies take center stage. Hum Antibodies. 2001;10:127-142.
48. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
49. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol. 2002;29(3 suppl 11):38-43.
50. Schneider JW, Chang AY, Garratt A. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol. 2002;29(3 suppl 11):22-28.
51. Roche PC, Ingle JN. Increased HER2 with US Food and Drug Administration-approved antibody [letter]. J Clin Oncol. 1999;17:434.
52. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852-854.
53. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894-2904.
54. Mass RD, Press MF, Anderson S, et al. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH) [abstract]. Proc ASCO. 2001:85.
55. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
56. Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 2002;82:1007-1014.
57. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines for the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-1878.
58. Piccart-Gebhart MJ. Herceptin: the future in adjuvant breast cancer therapy. Anticancer Drugs. 2001;12 suppl 4:S27-S33.
59. Hortobagyi GN. Overview of treatment results with trasmzumab (Herceptin) in metastatic breast cancer. Semin Oncol. 2001;28(6 suppl 18):43-47.
60. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550-6565.
61. Baselga J. The EGFR as a target for anticancer therapy: focus on cetuximab. Eur J Cancer. 2001;37 suppl 4:S16-S22.
62. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002;29(1 suppl 4):27-36.
63. Leonard DS, Hill AD, Kelly L, et al. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. Br J Surg. 2002;89:262-271.
64. Reynolds T. Biotech firm faces challenges from FDA, falling stock prices. J Natl Cancer Inst. 2002;94:326-328.
65. Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J. 2001;7 suppl 3:S120-S128.
66. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 2002;9(2 suppl):36-44.
67. Chen HX, Gore-Langton RE, Cheson BD. Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab [directory]. Oncology. 2001;15:1017, 1020, 1023-1026.
68. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol. 2002;29(3 suppl 11):29-37.
69. Berlin JD. Targeting vascular endothelial growth factor in colorectal cancer. Oncology. 2002;16(8 suppl 7):13-15.
70. Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol. 2001;40:17-24.
71. Haller DG. Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer. Semin Oncol. 2001;28(1 suppl 1):25-30.
72. Kirchner EM, Gerhards R, Voigtmann R. Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells. Ann Oncol. 2002;13:1044-1048.
73. Foon KA, John WJ, Chakraborty M, et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999;17:2889-2895.
74. Kindler HL, Shulman KL. Metastatic colorectal cancer. Curr Treat Options Oncol. 2001;2:459-471.
75. Indar A, Maxwell-Armstrong CA, Durrant LG, et al. Current concepts in immunotherapy for the treatment of colorectal cancer. J R Coll Surg Edinb. 2002;47:458-474.
76. Valone FH, Kaufman PA, Guyre PM, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the protooncogene HER-2/neu. J Clin Oncol. 1995;13:2281-2292.
77. Curnow RT. Clinical experience with CD64-directed immunotherapy: an overview. Cancer Immunol Immunother. 1997;45:210-215.
78. Holmes EH. PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin Investig Drugs. 2001;10:511-519.
79. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629-3634.
80. Bander NH, Nanus D, Goldsmith S, et al. Phase I trial of humanized monoclonal antibody (mAb) to prostate specific membrane antigen/extracellular domain (PSMAext) [abstract]. Proc ASCO. 2002:722.
81. Fracasso G, Bellisola G, Cingarlini S, et al. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate. 2002;53:9-23.
82. Mulders PF, De Mulder PH. The role of adjuvant immunotherapy in renal cell carcinoma. Curr Urol Rep. 2002;3:44-49.
83. Liu Z, Smyth FE, Renner C, et al. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother. 2002;51:171-177.
84. Foon KA, Lutzky J, Baral RN, et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol. 2000;18:376-384.
85. Bier H, Hoffmann T, Hauser U, et al. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol. 2001;47:519-524.
86. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002;29(1 suppl 4):47-50.
87. Rowinsky EK, Ochoa L, Patnaik A, et al. SB-408075, a tumor-activated immunoconjugate targeting the C242 CanAg antigen with a potent maytansinoid payload; phase 1, pharmacokinetic (PK) and biological studies [abstract]. Proc ASCO. 2002:118.
88. Fossella FV, Tolcher A, Elliott M, et al. Phase 1 trial of the monoclonal antibody conjugate BB-10901, for relapsed/refractory small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors [abstract]. Proc ASCO. 2002:1232.
89. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110-124.
90. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol. 2002;20:1932-1941.
91. Petricoin EF, Zoon KC, Kohn EC, et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002;1:683-695.